Trial Profile

A Phase 2, Single-center, Open-label Study of Setmelanotide in Patients With Prader-Willi Syndrome

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 15 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Setmelanotide (Primary)
Indications Prader-Willi syndrome
Focus Adverse reactions
Sponsors Rhythm

Most Recent Events

07 May 2025 According to a Rhythm Pharmaceuticals media release, the company plans to Complete enrollment in the setmelanotide Phase 2 trial in PWS in the second half of 2025.
07 May 2025 According to a Rhythm Pharmaceuticals media release, on April 7, 2025, the company announced it dosed the first patients with Prader-Willi syndrome (PWS) in a 26-week, open-label Phase 2 trial of setmelanotide.
27 Feb 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com